Quantitative structure-activity relationship study of N-(3-oxo-3,4- dihydro-2H-benzol[1,4]thiazine-6-carbonyl)guanidines as potent na/h exchange inhibitors

Chemical and Pharmaceutical Bulletin

Volumn 48, Issue 6, 2000, Pages 843-849

  Yamamoto, Takeshi ^a   Hori, Manabu ^a   Watanabe, Ikuo ^a   Harada, Kengo ^a   Ikeda, Shoji ^a   Ohtaka, Hiroshi ^a  

^a Nippon Organon KK   (Japan)

Author keywords

N (2H benzo 1,4 thiazine 6 carbonyl)guanidine; Na H exchange inhibitor; Quantitative structure activity relationship

Indexed keywords

1 (3,4 DIHYDRO 4 ISOPROPYL 2,2 DIMETHYL 3 OXO 2H 1,4 BENZOXAZINE 6 CARBONYL)GUANIDINE; GUANIDINE DERIVATIVE; N (3 OXO 3,4 DIHYDRO 2H BENZO[1,4]THIAZINE 6 CARBONYL)GUANIDINE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ARTICLE; DRUG POTENCY; DRUG SOLUBILITY; HYDROPHOBICITY; PROTON SODIUM EXCHANGE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 0033936203     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.48.843     Document Type: Article

References (18)

1. a) Wakabayashi S., Shigekawa M., Pouyssegur J., Physiol. Rev., 77, 51-74 (1997);
2. b) Fröhlich O., Karmazyn M., Cardiovasc. Res., 36, 138-148 (1997).
3. a) Garcia-Dorado D., Gonzalez M. A., Barrabés J. A., Ruiz-Meana M., Solares J., Lidon R.-M., Blanco J., Puigfel Y., Piper H. M., Soler-Soler J., Cardiovasc. Res., 35, 880-889 (1997);
4. b) Miura T., Ogawa T., Suzuki K., Goto M., Shimamoto K., J. Am. Coll. Cardiol., 29, 693-701 (1997).
5. Meng H.-P., Maddaford T. G., Pierce G. N., Am. J. Physiol., 264, H1831-H1835 (1993).
6. Yasutake M., Ibuki C., Hearse D. J., Avkiran M., Am. J. Physiol., 267, H2430-H2440 (1994).
7. Scholz W., Albus U., Counillon L., Gögelein H., Lang H.-J., Linz W., Weichen A., Schölkens B. A., Cardiovasc. Res., 29, 260-268 (1995).
8. Yamamoto T., Hori M., Watanabe I., Tsutsui H., Harada K., Ikeda S., Ohtaka H., Chem. Pharm. Bull., 45, 1282-1286 (1997).
9. Yamamoto T., Hori M., Watanabe I., Tsutsui H., Harada K., Ikeda S., Maruo J., Morita T., Ohtaka H., Chem. Pharm. Bull., 45, 1975-1983 (1997).
10. CLOGP program. Version 4.42, Daylight Chemical Information Systems, Inc., Irvine. The clogP of aroylguanidines was determined by subtraction of 0.3, due to the methyl group, from the calculated clogP value of the N-methyl-N-carbonylguanidine derivatives. The value of 0.3 was calculated by averaging the difference (0.46) between guanidine (clogP= - 1.50) and its methyl derivative (clogP= - 1.04) and the difference (0.15) between phenethylamine (clogP=1.28) and its methyl derivative (clogP=1.43).
11. Lien E. J., "Drug Design," Vol. 5, ed. by Ariens E. J., Academic Press, Inc., New York, 1975, pp. 81-132.
12. Yamamoto T., Hori M., Watanabe I., Tsutsui H., Harada K., Ikeda S., Maruo J., Morita T., Ohtaka H., Chem. Pharm. Bull., 46, 1716-1723 (1998).
13. Rosskopf D., Morgenstern E., Scholz W., Osswald U., Siffert W., J. Hypertension, 9, 231-238 (1991).
14. Verloop A., Hoogenstraaten W., Tipker J., "Drug Design," Vol. 7, ed. by Ariens E. J., Academic Press, Inc., New York, 1976, pp. 165-207.
15. 61 Thus, the calculated factor based on the different rings is 0.58 ( = 1.043 × [0.20-(-0.36)]).
16. Tagliavini S., Genedani S., Bertolini A., Bazzani C., Eur. J. Pharmacol., 194, 7-10 (1991).
17. Dunbar J. C., Reinholt L., Henry R. L., Mammen E., Diabet. Res. Clin. Prac., 9, 265-272 (1990).
18. Walker M. J. A., Curtis M. J., Hearse D. J., Campbell R. W. F., Janse M. J., Yellon D. M., Cobbe S. M., Coker S. J., Harness J. B., Harron D. W. G., Higgins A. J., Julian D. G., Lab J. J., Manning A. S., Northover B. J., Parratt J. R., Riemersma R. A., Riva E., Russell D. C., Sheridan D. J., Winslow E., Woodward B., Cardiovasc. Res., 22, 447-455 (1988).